Abnormal Mitochondrial Bioenergetic and Motility Signatures in Human Blood Cells as Indices of Acute Poisoning in Patients

项目摘要 与中毒有关的事件导致45万多人住院，75万人急诊（艾德） 艾德诊症的费用每年超过5.5亿元。据保守估计， 在美国，每年有20，000例损伤是由于线粒体毒物（例如，一氧化碳（CO）、氰化物 (CN)硫化氢（H2S）、磷化物），导致线粒体抑制，直接导致心脏骤停 和/或休克。暴露于线粒体抑制剂发生在各种环境中，包括火灾，职业 和工业接触，自杀和潜在的空气，水和食物传播的恐怖主义制剂， 武器化气体和液体此时的治疗是有限的，目前依赖于支持性护理 以及使用不同有效性的解毒剂治疗。这些线粒体死亡的主要原因 抑制剂是循环性休克和心脏骤停。尽管目前有治疗方法， 由于在知识方面存在重大差距，包括线粒体与 对急性线粒体中毒的反应功能障碍和缺乏足够的分子或细胞为基础的 目标导向治疗的指标。我的长期目标是识别出 线粒体生物能量学和动力学在人类血细胞以及应用一种新的药理学 脑靶向治疗策略。我的核心假设，是基于我的相关理论， 出版物和初步数据发现，在这个赠款，是有相当大的变化，复杂的联系， 活性，活性氧和动态响应急性中毒。血细胞也可以作为替代物 受影响组织的线粒体功能障碍的标志物。目前还没有直接的临床试验 以与急性患者护理相关的时间敏感方式测量线粒体功能。实验 本申请中提出的方法将应用各种参数的测量或评估， 从中毒患者获得的分离的人血细胞中的线粒体生物能量学和动力学。我们 还将应用一种新的药理学策略，用于人类血细胞中的线粒体定向治疗 以受控的方式暴露于选择的线粒体毒素。拟议研究的基本原理是 发展一个清楚的理解，出现在线粒体生物能量学和运动功能障碍， 对线粒体毒物的反应和正常线粒体功能的恢复， 实施有效治疗。

Project Summary Poison-related incidents account for over 450,000 hospitalizations and 750,000 emergency department (ED) visits, with the yearly cost for ED visits exceeding $550 million. It is conservatively estimated that 5,000 deaths per year and 20,000 injuries in the US are due to mitochondrial poisons (e.g., carbon monoxide (CO), cyanide (CN), hydrogen sulfide (H2S), phosphides) resulting in mitochondrial inhibition leading directly to cardiac arrest and/or shock. Exposure to mitochondrial inhibitors occurs in a variety of settings, including fires, occupational and industrial exposures, suicide and potential air-, water- and food-borne terrorism agents such as weaponized gases and liquids. Treatment at this is time is limited and currently depends on supportive care and use of antidotal therapy of variable effectiveness. The primary cause of death to these mitochondrial inhibitors is circulatory shock and cardiac arrest. Despite currently available treatments, morbidity and mortality remains high due to significant gaps in knowledge, including the relationship between mitochondrial dysfunction in response to acute mitochondrial poisoning and the lack of adequate molecular or cell-based indices for goal-directed treatment. My long-term goal is to identify characteristic signatures of abnormalities in mitochondrial bioenergetics and dynamics in human blood cells as well as apply a new pharmacological strategy of mitochondrial-directed therapy. My central hypothesis, formulated on the basis of my relevant publications and preliminary data found in this grant, is that there are considerable changes in complex-linked activity, ROS and dynamics in response to acute poisoning. Also that blood cells may be used a surrogate marker of mitochondrial dysfunction of affected tissue. At this time there are no clinical tests that directly measure mitochondrial function in a time-sensitive manner relevant to acute patient care. The experiments proposed in this application will apply the measurement or assessment of various parameters defining mitochondrial bioenergetics and dynamics in isolated human blood cells obtained from poisoned patients. We will also apply a new pharmacologic strategy for mitochondrial directed treatment in human blood cells exposed to select mitochondrial poisons in a controlled manner. The rationale for the proposed research is develop a clear understanding of the dysfunction that appears in mitochondrial bioenergetics and motility in response to mitochondrial poisons and the restoration of normal mitochondrial function that occurs with implementation of effective treatment.